Trial Profile
To compare the efficacy of Natalizumab and Fingolimod on cognitive functions in patients with relapsing-remitting Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Nov 2017
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary) ; Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 28 Oct 2017 Results presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
- 21 Nov 2016 New trial record